A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...
Survival disparities in small intestine carcinoid tumors: A SEER-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback